Barakah Profits › United States stocks A–Z

Is Atara Biotherapeutics, Inc. (ATRA) halal?

No. Atara Biotherapeutics, Inc. (ATRA) does not pass our halal screen, as of 18 November 2026. It fails on non-permissible income (< 5%).

NASDAQ · Healthcare · Screened 18 November 2026. Its verdict has not changed since our public ledger began on 24 September 2026.

The four checks

Business activityPassFrom the 10-K (2025): Atara Biotherapeutics' core business involves the development and commercialization of T-cell immunotherapies, which is entirely permissible, with no non-permissible or doubtful revenue streams identified.
Interest-bearing debtPassTotal debt is 16.1% of market cap (limit 30%).
Cash & interest-bearing securitiesPassCash & securities are 16.1% of market cap (limit 30%).
Non-permissible income (< 5%)FailInterest income is 7.0% of revenue (limit 5%). The annual report shows no other non-permissible revenue.

Verdict history

No changes recorded since 24 September 2026.

See every change across all stocks on the public verdict ledger.

Frequently asked questions

Is Atara Biotherapeutics, Inc. stock halal?

No. Atara Biotherapeutics, Inc. (ATRA) does not pass our halal screen, as of 18 November 2026. It fails on non-permissible income (< 5%).

Why can Atara Biotherapeutics, Inc.'s halal status change?

Two of the tests compare debt and cash with the company's market value. When the share price moves, those ratios move, so a stock can cross the 30% line without the business changing at all. Its verdict has not changed since our public ledger began on 24 September 2026.

How does Barakah Profits screen stocks?

We use an AAOIFI-style screen: the business itself must be permissible, interest-bearing debt and interest-bearing cash must each be under 30% of market value, and non-permissible income must be under 5% of revenue. It is an automated estimate, not a fatwa.

Check any stock

Free halal check for US, Australian, Malaysian and Singapore stocks.

Check a stock

AAOIFI-style screen by Barakah Profits. Automated estimate, not a fatwa. Always confirm with a qualified scholar before investing. Financial data provided by Twelve Data. This is general information, not financial advice.